Kidney Cancer

First-line Pazopanib May Improve Outcomes in Advanced RCC

First-line Pazopanib May Improve Outcomes in Advanced RCC

By

Treatment-naïve patients with advanced clear-cell renal cell carcinoma had significantly longer progression-free survival when treated with pazopanib instead of temsirolimus.

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

Metastatic RCC Treatment With Nivolumab Confirmed Safe, Efficacious

By

The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial.

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

Axitinib-Pembrolizumab Combo Promising for Advanced RCC

By

In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma.

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

Cytoreductive Nephrectomy May Up Survival in Papillary mRCC

By

Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not.

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

Metastatic Kidney Cancer Outcomes Improved With Combined Therapy

By

Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma.

Urologic Cancer Surgery Readmission Rate Highest for RC

Urologic Cancer Surgery Readmission Rate Highest for RC

By

In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.

Jury Still Out on Whether Immunotherapy Can Cure Metastatic RCC

Jury Still Out on Whether Immunotherapy Can Cure Metastatic RCC

Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.

Robotic Partial Nephrectomy Feasible for Larger Kidney Tumors

Robotic Partial Nephrectomy Feasible for Larger Kidney Tumors

By

No greater risks for upstaging or positive surgical margins were observed among patients who underwent RPN for cT2a tumors over the short term.

Kidney Cancer Progression Linked to Preop Cardiovascular Biomarkers

Kidney Cancer Progression Linked to Preop Cardiovascular Biomarkers

By

Elevated serum levels of BNP and NT-proBNP prior to nephrectomy are associated with an increased likelihood of RCC progression.

Regional variation in CT imaging is associated with nephrectomy risk

1. Regional variation in cumulative risk of an individual having a chest or abdominal CT in the United States was positively correlated with the risk of both total and partial nephrectomy, as well as any renal procedure (including renal ablation). 2. This association may reflect incidental detection and over-diagnosis of renal masses, with an increased []

RCC Treatment Costs Could Negatively Affect Health

RCC Treatment Costs Could Negatively Affect Health

Access to treatment should be considered as important as the research leading to clinical improvements.

Radical Nephrectomy Linked With Worse Kidney Function, Survival

Radical Nephrectomy Linked With Worse Kidney Function, Survival

By

Patients who underwent radical nephrectomy had 2-fold greater decline in eGFR decline and 2-fold greater mortality compared with those who had a partial nephrectomy.

Cabozantinib Improves Survival, Response in Bone-metastatic RCC

Cabozantinib Improves Survival, Response in Bone-metastatic RCC

Patients who received cabozantinib were also less likely to have skeletal-related events (23% vs 29% with everolimus).

3D Printing Surgical Models for Kidney Cancer Care

3D Printing Surgical Models for Kidney Cancer Care

By

Renal & Urology News spoke with Jonathan Silberstein, MD, about creating surgical models using a 3D printer.

SABR for Renal Cell Carcinoma Offers Excellent Outcomes

SABR for Renal Cell Carcinoma Offers Excellent Outcomes

By

Stereotactic ablative radiotherapy is associated with high 2- and 4-year rates of local cancer control and progression-free and cancer-specific survival.

Conversion of Robotic Partial to Radical Nephrectomy Is Uncommon

Conversion of Robotic Partial to Radical Nephrectomy Is Uncommon

By

In a multinational, prospective study, just 5% of cases converted.

Adverse Events Up for Autoimmune Disease Pts on Checkpoint Inhibitors

Adverse Events Up for Autoimmune Disease Pts on Checkpoint Inhibitors

Most patients with cancer, autoimmune disease have improvement in events without discontinuing therapy.

Fatigue Tied With Sorafenib, Sunitinib Use in Renal Cell Carcinoma

Fatigue Tied With Sorafenib, Sunitinib Use in Renal Cell Carcinoma

Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.

Partial Nephrectomy Improves Survival in cT1b RCC Cases

Partial Nephrectomy Improves Survival in cT1b RCC Cases

By

Partial nephrectomy was associated with decreased odds of death versus radical nephrectomy among patients with cT1b but not cT2 renal cell carcinoma.

FDA Approves Cabometyx for First-Line Treatment of Advanced RCC

FDA Approves Cabometyx for First-Line Treatment of Advanced RCC

Treatment with cabozantinib led to a clinically meaningful improvement in progression-free survival compared with sunitinib.

Cytoreductive Nephrectomy Benefits for Metastatic RCC Demonstrated

Cytoreductive Nephrectomy Benefits for Metastatic RCC Demonstrated

By

Patients who underwent cytoreductive nephrectomy for metastatic non-clear cell renal cell carcinoma had a significantly decreased risk of cancer-related mortality.

Kidney Cancer Bone Metastasis Predictors Id'd

Kidney Cancer Bone Metastasis Predictors Id'd

By

Levels of alkaline phosphatase, calcium, and hemoglobin can independently predict bone metastasis in patients with renal cell carcinoma, Chinese investigators report.

FDA Approves Sunitinib for Adjuvant Treatment of RCC

FDA Approves Sunitinib for Adjuvant Treatment of RCC

By

At 5 years, 59.3% of patients treated with sunitinib were free from recurrence versus 51.3% who received placebo.

Radical Nephrectomy Costs, Operating Time Greater With Robotics

Radical Nephrectomy Costs, Operating Time Greater With Robotics

By

Robotic-assisted radical nephrectomy (RN) is associated with higher hospital costs and prolonged operating time compared with laparoscopic RN.

Blood Transfusion Predicts Worse Outcomes After Nephrectomy for RCC

Blood Transfusion Predicts Worse Outcomes After Nephrectomy for RCC

By

Perioperative blood transfusion is associated with increased risks of tumor recurrence, metastatic progression, and cancer-related mortality.

Overweight-Related Cancers Common in the US

Overweight-Related Cancers Common in the US

40% of cancer diagnoses tied to extra weight; rate higher in older individuals, females.

RCC Subtypes Affect Post-Surgery Cancer-Related Mortality Risk

RCC Subtypes Affect Post-Surgery Cancer-Related Mortality Risk

By

Patients with papillary versus clear cell renal cell carcinoma have a 24% decreased risk of dying from their cancer.

CKD Risk Lower With Partial Nephrectomy

CKD Risk Lower With Partial Nephrectomy

By

In a study, partial nephrectomy was associated with a 66% lower risk for stage 4 or higher CKD versus radical nephrectomy.

Various Neurological Complications Tied to Anti-PD-1 Therapy

Various Neurological Complications Tied to Anti-PD-1 Therapy

The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.

FDA Approves First Biosimilar for Kidney Cancer Treatment

FDA Approves First Biosimilar for Kidney Cancer Treatment

Mvasi, which is approved to treat colorectal, lung, brain, kidney, and cervical cancer, was found to be biosimilar to the drug Avastin.

Sign Up for Free e-newsletters